OCEANSIDE,
CA -- April 10, 2017
-- InvestorsHub NewsWire -- Therapeutics Solutions
International, Inc., (OTC
PINK: TSOI) announced today the filing of a new patent and
exclusive licensing agreement with majority owned subsidiary
Emvolio, Inc.
The patent describes methods of cancer treatment through the
administration of proteins or specific peptides found on tumor stem
cells in vivo, in a manner eliciting monocyte or dendritic cell
migration in order to allow uptake of proteins or peptides,
followed by administration of a maturation signal in vivo. The
invention provides for treatment of cancer through induction of
anticancer immunity and/or immunity towards tumor initiating stem
cells.
The new product, called StemVacs™, is a subcutaneously
administered vaccine comprised of immune stimulatory peptides
resembling cancer stem cell specific proteins. StemVacs has now
been licensed exclusively to Emvolio, Inc. (EMVO) a majority owned
subsidiary of TSOI.
"This is a great day for TSOI and EMVO as we continue in our
quest to bring personalized medicine into the 21st century
and with the out-licensing of this IP to Emvolio that time is one
day closer. We are excited for Emvolio and the future of
immunotherapy," said Timothy Dixon, President and CEO of
Therapeutic Solutions International.
"Tumor stem cells are considered the origin of all tumors, as
well as the seeds that allow the tumor to return in cases of
relapse. By leveraging the body's own natural resources to
specifically attack cancer stem cells, we believe we are on track
for developing a promising immunotherapy for cancer patients," said
Dr. Thomas Ichim, Director of Therapeutic Solutions International
and co-inventor of StemVacs.
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new
products can be viewed on www.projuvenol.com and products can be
ordered at www.youcanordernow.com.
About Emvolio, Inc.
The Company's corporate website is www.emvolio.com. Emvolio, Inc. is a Delaware
corporation.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.